Zacks Research Downgrades Aytu BioPharma (NASDAQ:AYTU) to Strong Sell

Aytu BioPharma (NASDAQ:AYTU) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other brokerages have also issued reports on AYTU. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Friday, January 9th. Ascendiant Capital Markets lifted their target price on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Wall Street Zen upgraded Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Stock Down 3.3%

NASDAQ:AYTU opened at $2.64 on Tuesday. Aytu BioPharma has a one year low of $0.95 and a one year high of $3.07. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.16 and a quick ratio of 1.03. The company has a market cap of $28.33 million, a PE ratio of -0.69 and a beta of 0.27. The firm’s 50 day simple moving average is $2.51 and its 200 day simple moving average is $2.38.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.79). The business had revenue of $15.17 million during the quarter, compared to analyst estimates of $12.17 million. Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%.

Institutional Trading of Aytu BioPharma

Large investors have recently made changes to their positions in the company. Daytona Street Capital LLC acquired a new position in Aytu BioPharma during the 4th quarter worth approximately $26,000. Rothschild Wealth LLC bought a new position in Aytu BioPharma in the fourth quarter worth approximately $52,000. Bellevue Asset Management LLC acquired a new stake in Aytu BioPharma in the fourth quarter valued at approximately $65,000. XTX Topco Ltd acquired a new stake in Aytu BioPharma in the fourth quarter valued at approximately $67,000. Finally, DRW Securities LLC bought a new stake in shares of Aytu BioPharma during the fourth quarter valued at approximately $76,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.